Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - July 2012

The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of July 2012. This month there are two technology appraisals that impact upon primary care.

The adalimumab (Humira®) for the treatment of moderate to severe ulcerative colitis appraisal has been terminated and the treatment cannot be recommended. No evidence submission was made by the manufacturer or technology sponsor.

Rivaroxaban (Xarelto®) is recommended as an option for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. This treatment was evaluated against warfarin and low molecular weight heparins (LMWH). It is noted that in the short term this treatment is less expensive than other options. Over longer periods it becomes more expensive but the additional expense is justified by additional benefits in terms of less monitoring compared to warfarin and oral route of administration compared to LMWH.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - July 2012' on Email Share 'NICE Guidance - July 2012' on Delicious Share 'NICE Guidance - July 2012' on Digg Share 'NICE Guidance - July 2012' on Facebook Share 'NICE Guidance - July 2012' on Google+ Share 'NICE Guidance - July 2012' on reddit Share 'NICE Guidance - July 2012' on StumbleUpon Share 'NICE Guidance - July 2012' on Twitter

atomic-wealth

No Comments to “NICE Guidance - July 2012”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,515 spam comments.

atomic-wealth
fond-illness
summer